ABBOTT PARK, Ill. and PARIS,
Sept. 16, 2019 /PRNewswire/ -- Abbott
(NYSE: ABT) and Sanofi are partnering to integrate glucose sensing
and insulin delivery technologies that would help to further
simplify how people with diabetes manage their condition. The two
companies will take an innovative approach to connected care by
developing tools that combine the revolutionary FreeStyle Libre
technology with Sanofi′s insulin dosing information for future
smart pens, insulin titration apps and cloud software.
"As the global leader in continuous glucose monitoring, we see a
significant opportunity to impact the health of millions of people
living with diabetes by developing new tools and connectivity with
Sanofi, a leader in the insulin space," said Jared Watkin, senior vice president, Diabetes
Care, Abbott. "Diabetes can be overwhelming as it is an
information-rich condition with various streams of data from
multiple devices. Building a digital ecosystem around FreeStyle
Libre simplifies the user experience by consolidating how people
get their data – both through offering Abbott′s digital health
tools and by working with other diabetes and technology
The non-exclusive collaboration will initially enable data
sharing, at the consent of the user, between Abbott′s FreeStyle
Libre mobile app and cloud software and Sanofi′s connected insulin
pens, apps and cloud software that are currently in development.
This data sharing will enable both people with diabetes and their
doctors to make better informed treatment decisions around
medication, nutrition and lifestyle.
"For close to a century, Sanofi has been supporting those living
with diabetes through our robust portfolio of medicines. This
strategic relationship with Abbott is representative of the next
evolution of our commitment for better diabetes care by
incorporating digital tools into the daily life of people living
with diabetes," said Gustavo Pesquin, senior vice president of
Global Diabetes and Cardiovascular Franchise at Sanofi. "By
partnering with Abbott, we are a step closer to realizing our
connected ecosystem, which would help improve control and the
quality of life decision cycle for patients through individualized
glycemic management of diabetes."
Sanofi is currently working to provide connected pens, apps and
cloud software that will be compatible with the FreeStyle Libre
system and its compatible digital health tools. The two companies
aim to bring this to people with diabetes within the next few
years, pending local regulatory approvals.
Sanofi is dedicated to supporting people
through their health challenges. We are a global biopharmaceutical
company focused on human health. We prevent illness with vaccines,
provide innovative treatments to fight pain and ease suffering. We
stand by the few who suffer from rare diseases and the millions
with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
Sanofi, Empowering Life
About the FreeStyle Libre System
Libre, the #1 sensor-based glucose monitoring system used
worldwide,i reads glucose levels through
a sensor that can be worn on the back of the upper arm eliminating
the need for fingersticksii. FreeStyle Libre has changed
the lives of more than 1.5 million people across 46
countriesiii, and has secured partial or full
reimbursement in 33 countries, including Canada, France, Ireland, Japan, the United
Kingdom, and the U.S.
Abbott's FreeStyle LibreLinkiv app enables
users to capture and view their real-time glucose levels, their
eight-hour glucose history, and how their glucose is currently
changing on their smartphone. LibreViewv is a
secure cloud-based diabetes management system that gives people
with diabetes and healthcare professionals clear,
easy-to-understand reports from the FreeStyle Libre system.
LibreLinkUpvi is an app that enables caregivers of
people living with diabetes to remotely monitor their loved ones'
glucose readings. For more information, please visit
Important safety information:
Abbott is a global healthcare leader
that helps people live more fully at all stages of life. Our
portfolio of life-changing technologies spans the spectrum of
healthcare, with leading businesses and products in diagnostics,
medical devices, nutritionals and branded generic medicines. Our
103,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at
www.linkedin.com/company/abbott-/, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews and
i Data on file, Abbott Diabetes Care. Data based
on the number of users worldwide for the FreeStyle Libre system
compared to the number of users for other leading personal use,
sensor-based glucose monitoring systems.
ii A finger prick test using a blood glucose meter
is required during times of rapidly changing glucose levels when
interstitial fluid glucose levels may not accurately reflect blood
levels or if hypoglycaemia is reported by the system or when
symptoms do not match the systems readings.
iii Data on file, Abbott Diabetes Care
iv The FreeStyle LibreLink app is compatible with
NFC enabled phones running Android OS 5.0 or higher and with iPhone
7 and higher running OS 11 and higher.
v LibreView is developed and distributed by Newyu,
vi LibreLinkUp is a mobile application, developed
and provided by Newyu, Inc. Use of LibreLinkUp requires
registration with LibreView, a service provided by Abbott and